May. 9 at 9:21 PM
$RNAZ
The Valuation of a "Successful" Drug
In the pharmaceutical industry, a company with a successful, approved drug is valued based on its projected annual sales rather than its current assets.
• Blockbuster Potential: The global market for advanced cancer treatments is projected to reach
$120–250 billion by 2032.
• Revenue Multiples: Commercial-stage biotech companies typically trade at 4x to 10x their annual revenue. If TTX-MC138 captured even 1% of that market (approx.
$1.2 billion in sales), a standard 5x multiple would imply a company valuation of
$6 billion.
• The "Step-Up" Effect: For a micro-cap like RNAZ with only ~833,000 shares outstanding, this would mathematically translate to a share price in the thousands. However, in reality, a company usually signs a strategic partnership or is acquired by Big Pharma long before reaching that stage to fund the massive costs of commercialization.
